Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
All content for On The Pen With Dave Knapp is the property of Bleav, Dave Knapp Founder of On The Pen and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
Wegovy and Ozempic Users: FDA's Scathing Report on Major Novo Factory
On The Pen With Dave Knapp
27 minutes 44 seconds
1 month ago
Wegovy and Ozempic Users: FDA's Scathing Report on Major Novo Factory
In this episode:
What the FDA warning really means for Wegovy, Ozempic, and Zepbound users
Why an OAI classification matters — and how it could affect GLP-1 access
How the FDA oversight system protects patients (and where it fails)
Why compounded GLP-1 medications exist in the first place
The bigger picture: access, safety, and patient rights
On The Pen With Dave Knapp
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
